WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317553
CAS#: 911-45-5 (free base)
Description: Clomifene or clomiphene is a selective estrogen receptor modulator (SERM) that has become the most widely prescribed drug for ovulation induction to reverse anovulation or oligoovulation. Clomiphene is a triphenylethylene nonsteroidal ovulatory stimulant evaluated for antineoplastic activity against breast cancer. Clomiphene has both estrogenic and anti-estrogenic activities that compete with estrogen for binding at estrogen receptor sites in target tissues. This agent causes the release of the pituitary gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to ovulation. It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system.
MedKoo Cat#: 317553
Name: Clomiphene free base
CAS#: 911-45-5 (free base)
Chemical Formula: C26H28ClNO
Exact Mass: 405.18594
Molecular Weight: 405.96
Elemental Analysis: C, 76.92; H, 6.95; Cl, 8.73; N, 3.45; O, 3.94
Synonym: Clomiphene; Clomifene; D; Chloramiphene; Omifin; Citrate; Clomiphene; Clomid; Androxal; Clomide; Clomifen; Clostilbegit; Dyneric; Gravosan; Klostilbegit; Serophene
IUPAC/Chemical Name: 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylethanamine
InChi Key: GKIRPKYJQBWNGO-QPLCGJKRSA-N
InChi Code: InChI=1S/C26H28ClNO/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23/h5-18H,3-4,19-20H2,1-2H3/b26-25-
SMILES Code: CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 405.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Xi W, Liu S, Mao H, Yang Y, Xue X, Lu X. Use of letrozole and clomiphene citrate combined with gonadotropins in clomiphene-resistant infertile women with polycystic ovary syndrome: a prospective study. Drug Des Devel Ther. 2015 Nov 11;9:6001-8. doi: 10.2147/DDDT.S83259. eCollection 2015. PubMed PMID: 26648691; PubMed Central PMCID: PMC4651359.
2: Oktem M, Guler I, Erdem M, Erdem A, Bozkurt N, Karabacak O. Comparison of The Effectiveness of Clomiphene Citrate versus Letrozole in Mild IVF in Poor Prognosis Subfertile Women with Failed IVF Cycles. Int J Fertil Steril. 2015 Oct-Dec;9(3):285-91. Epub 2015 Oct 31. PubMed PMID: 26644850; PubMed Central PMCID: PMC4671387.
3: Liu W, Dong S, Li Y, Shi L, Zhou W, Liu Y, Liu J, Ji Y. Randomized controlled trial comparing letrozole with laparoscopic ovarian drilling in women with clomiphene citrate-resistant polycystic ovary syndrome. Exp Ther Med. 2015 Oct;10(4):1297-1302. Epub 2015 Aug 19. PubMed PMID: 26622481; PubMed Central PMCID: PMC4578114.
4: Chen C, Yan Q, Liu K, Zhou X, Xian Y, Liang D, Zhao X, Guo X, Quan S. Endometrial Receptivity Markers in Mice Stimulated With Raloxifene Versus Clomiphene Citrate and Natural Cycles. Reprod Sci. 2015 Nov 23. pii: 1933719115616496. [Epub ahead of print] PubMed PMID: 26603317.
5: Azmoodeh A, Pejman Manesh M, Akbari Asbagh F, Ghaseminejad A, Hamzehgardeshi Z. Effects of Letrozole-HMG and Clomiphene-HMG on Incidence of Luteinized Unruptured Follicle Syndrome in Infertile Women Undergoing Induction Ovulation and Intrauterine Insemination: A Randomised Trial. Glob J Health Sci. 2015 Sep 1;8(4):45762. doi: 10.5539/gjhs.v8n4p244. PubMed PMID: 26573024.
6: Sharief M, Nafee NR. Comparison of letrazole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. J Pak Med Assoc. 2015 Nov;65(11):1149-52. PubMed PMID: 26564281.
7: Seckin B, Pekcan MK, Bostancı EI, Inal HA, Cicek MN. Comparison of pregnancy rates in PCOS patients undergoing clomiphene citrate and IUI treatment with different leading follicular sizes. Arch Gynecol Obstet. 2015 Nov 13. [Epub ahead of print] PubMed PMID: 26563313.
8: Vaiarelli A, Drakopoulos P, Blockeel C, De Vos M, van de Vijver A, Camus M, Cosyns S, Tournaye H, Polyzos NP. Limited ability of circulating anti-Müllerian hormone to predict dominant follicular recruitment in PCOS women treated with clomiphene citrate: a comparison of two different assays. Gynecol Endocrinol. 2015 Nov 20:1-4. [Epub ahead of print] PubMed PMID: 26559558.
9: Kuroda K, Kitade M, Kumakiri J, Jinushi M, Shinjo A, Ozaki R, Ikemoto Y, Katoh N, Takeda S. Minimum ovarian stimulation involving combined clomiphene citrate and estradiol treatment for in vitro fertilization of Bologna-criteria poor ovarian responders. J Obstet Gynaecol Res. 2015 Nov 10. doi: 10.1111/jog.12862. [Epub ahead of print] PubMed PMID: 26555576.
10: Ketabchi AA. Clomiphene Effects on Idiopathic Premature Ejaculation. Nephrourol Mon. 2015 Sep 16;7(5):e27281. doi: 10.5812/numonthly.27281. eCollection 2015 Sep. PubMed PMID: 26543830; PubMed Central PMCID: PMC4630386.